Temozolomide (TMZ)-challenged GBM cells strongly suppress pro inflammatory activity via enhanced transcription of PD-L1 but no other immune checkpoints, such as CD276, HVEM or galectin-925. This evidence concerns the gene CD274 and glioblastoma.